Outcomes of symptomatic compared to asymptomatic recurrences in patients with glioblastoma multiforme (GBM)

Objective Glioblastoma multiforme (GBM) is a nearly uniformly fatal brain tumor with a median recurrence rate of 7 months and survival of 14 months after multimodality treatment. We sought to evaluate outcomes based on the presence or absence of symptoms at the time of recurrence.